As one considers the challenges facing Ponatinib, and the upward path of '113, this company could give '113 the mantle of flagship product. If the '113 trials continue well, and criz failures continue at the 50% rate after a year, '113 would reach the $500M mark well ahead of Pona.
Still, big "if", and mN has to be a winner. and Pona needs to make some improvement for the company to stay independent. Tall order. Sadly, Pona's AE's will likely forever relegate it to 'last line' status, and Ariad should price it according ly.